Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Pipeline Review, H2 2016

  • ID: 3821630
  • Report
  • 72 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Asana BioSciences, LLC
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline Plc
  • Verastem, Inc.
  • MORE
Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Pipeline Review, H2 2016

Summary

‘Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Pipeline Review, H2 2016’, provides in depth analysis on Focal Adhesion Kinase (FAK or EC 2.7.10.2) targeted pipeline therapeutics.

The report provides comprehensive information on the Focal Adhesion Kinase (FAK or EC 2.7.10.2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Focal Adhesion Kinase (FAK or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Focal Adhesion Kinase (FAK or EC 2.7.10.2)
- The report reviews Focal Adhesion Kinase (FAK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Focal Adhesion Kinase (FAK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Focal Adhesion Kinase (FAK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Focal Adhesion Kinase (FAK or EC 2.7.10.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Focal Adhesion Kinase (FAK or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Focal Adhesion Kinase (FAK or EC 2.7.10.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Asana BioSciences, LLC
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline Plc
  • Verastem, Inc.
  • MORE
List of Figures

Introduction

Report Coverage

Focal Adhesion Kinase (FAK or EC 2.7.10.2) Overview

Therapeutics Development

Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Products under Development by Stage of Development

Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Products under Development by Therapy Area

Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Products under Development by Indication

Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Products under Development by Companies

Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Products under Development by Universities/Institutes

Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Companies Involved in Therapeutics Development

Asana BioSciences, LLC

Boehringer Ingelheim GmbH

GlaxoSmithKline Plc

Takeda Pharmaceutical Company Limited

Teva Pharmaceutical Industries Ltd.

Verastem, Inc.

Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Drug Profiles

ASN-006 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BI-853520 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CEP-37440 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cilengitide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CT-707 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTX-0294886 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTX-0294945 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

defactinib hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2256098 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Focal Adhesion Kinase for Solid Tumors - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit FAK for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Focal Adhesion Kinase for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VS-4718 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VS-6062 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Dormant Projects

Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Discontinued Products

Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Featured News & Press Releases

Jul 05, 2016: Study Published in Nature Medicine Highlights Potential Role of FAK Inhibition in Pancreatic Cancer

May 25, 2016: Iceni Pharmaceuticals launches as new company focusing on repurposing therapies in the field of oncology

May 04, 2016: Verastem Announces the Presentation of Clinical Data at iMig 2016

Mar 30, 2016: Verastem Announces Presentation of Scientific Data Supporting FAK Inhibition in Combination with Immunotherapy at the Keystone Symposium on Cancer Pathophysiology

Mar 16, 2016: Verastem to Present Data Supporting FAK/PYK2 Inhibition at the 2016 American Academy of Cancer Research Annual Meeting

Mar 16, 2016: Verastem to present data supporting FAK inhibition at the 2016 American Academy of cancer research annual meeting

Jan 21, 2016: Verastem to Present Scientific Data Supporting FAK Inhibition in Combination with Immune Checkpoint Inhibitors at Immunotherapy World 2016

Jan 06, 2016: Washington University in St. Louis Initiates Clinical Study of Verastem’s VS-6063 in Combination with Merck’s Pembrolizumab and Gemcitabine in Pancreatic Cancer

Sep 28, 2015: Verastem Stops Enrollment Due to Futility in the Command Study of Vs-6063 for the Treatment of Malignant Pleural Mesothelioma

Sep 17, 2015: Verastem Announces Presentation On VS-6063 at ESMO/ECCO 2015

Sep 10, 2015: Verastem Presents Clinical and Preclinical Data at the 16th World Conference on Lung Cancer

Aug 26, 2015: Verastem to Present Data at the 16th World Conference on Lung Cancer

Dec 11, 2014: Verastem Presents Data at the 2014 San Antonio Breast Cancer Symposium

Dec 04, 2014: Verastem to Present Data on VS-6063 at the 2014 San Antonio Breast Cancer Symposium

Dec 04, 2014: Verastem to Present Data on VS-4718 at the 2014 San Antonio Breast Cancer Symposium

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Number of Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016 (Contd..1)

Number of Products under Investigation by Universities/Institutes, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Pipeline by Asana BioSciences, LLC, H2 2016

Pipeline by Boehringer Ingelheim GmbH, H2 2016

Pipeline by GlaxoSmithKline Plc, H2 2016

Pipeline by Takeda Pharmaceutical Company Limited, H2 2016

Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016

Pipeline by Verastem, Inc., H2 2016

Dormant Projects, H2 2016

Dormant Projects (Contd..1), H2 2016

Discontinued Products, H2 2016 58List of Figures

Number of Products under Development for, H2 2016

Number of Products under Development by Top 10 Indication, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Asana BioSciences, LLC
Boehringer Ingelheim GmbH
GlaxoSmithKline Plc
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
Verastem, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll